NEPA Revalidation Sample Clauses

NEPA Revalidation. Circlepoint will conduct the environmental analyses described below and will complete the NEPA Conclusion section of the Caltrans CEQA/NEPA Revalidation form (Revalidation form), attaching continuation sheets, as necessary. This will include preparing a description of the changes in the project design based on information provided by Xxxx Xxxxxx; a discussion of the extent to which there may have been changes in the environmental setting; a discussion of changes in environmental circumstances; changes to the environmental impacts of the Project; changes to avoidance, minimization, and/ or mitigation measures; and changes to environmental commitments. To assess the potential for changes to impacts for environmental resources other than biological, Circlepoint will prepare a Technical Studies Review Memorandum to assess whether the following technical studies remain valid given the proposed change to the Project: Hazardous Materials Technical Memorandum, Water Quality Assessment Report, Land Use Technical Memorandum, Noise Technical Memorandum, Transportation Technical Memorandum, Visual Technical Memorandum, and Historic Properties Survey Report. The preparation of the Technical Studies Review Memorandum will include a desktop analysis using tools such as Google Earth and the State Water Resources Control Board’s Geotracker database of contaminated sites. It is assumed that no site visit will be required. To assess the potential for changes to impacts to biological resources, Circlepoint’s subconsultant Kleinfelder will update the background literature review of the Project area to identify any new potential sensitive resources within the vicinity of project activities. Resources to be reviewed include California Natural Diversity Database (CNDDB) for records of special-status species within five miles of the Project locations, current USFWS and NMFS species lists for the project area, USFWS designated critical habitat within five miles of the Project areas, National Wetlands Inventory (NWI) for wetlands and waterways near the Project areas, and current Project area aerial imagery. Kleinfelder biologists will conduct a site visit to verify documented conditions in the previously surveyed project areas and to document conditions in the proposed location of the pedestrian bridge. The pedestrian bridge will be located within previously surveyed areas. Kleinfelder does not expect substantial changes to site conditions identified in 2019 surveys and described in...
AutoNDA by SimpleDocs

Related to NEPA Revalidation

  • Validation To validate the notice requirements outlined in Section 5.3, the Assuming Institution shall provide the Receiver (i) an Affidavit of Publication to meet the publication requirements outlined in Section 5.3(a) and (ii) the Assuming Institution will prepare an Affidavit of Mailing in a form substantially similar to Exhibit 2.3B after mailing the seven (7) day Notice to Depositors as required under Section 5.3(b).

  • Validation Review In the event OIG has reason to believe that: (a) Good Shepherd’s Claims Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good Shepherd’s final Annual Report shall be initiated no later than one year after Good Shepherd’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Project Implementation 2. The Borrower shall:

  • How to Obtain Prescription Drug Preauthorization To obtain prescription drug preauthorization, the prescribing provider must submit a prescription drug preauthorization request form. These forms are available on our website or by calling the number listed for the “Pharmacist” on the back of your ID card. Prescription drugs that require preauthorization will only be approved when our clinical guidelines are met. These guidelines are based upon clinically appropriate criteria that ensure that the prescription drug is appropriate and cost- effective for the illness, injury or condition for which it has been prescribed. We will send you written notification of the prescription drug preauthorization determination within fourteen (14) calendar days of the receipt of the request. How to Request an Expedited Preauthorization Review You may request an expedited review if the circumstances are an emergency. Due to the urgent nature of an expedited review, your prescribing provider must either call or fax the completed form and indicate the urgent nature of the request. When an expedited preauthorization review is received, we will respond to you with a determination within seventy-two (72) hours or less. If we deny your request for preauthorization, you can submit a medical appeal. See Appeals in Section 5 for information on how to file a medical appeal. Formulary Exception Process When a prescription drug is not on our formulary, you can request that this plan cover the drug as an exception. To request a formulary exception, complete a Coverage Exception form (located on our website), contact our Customer Service Department, or have your prescribing provider submit a request for you. We will respond to you with a determination within seventy- two (72) hours following receipt of the request. For standard exception reviews, if the exception is approved, we will cover the prescription drug for the duration of the prescription, including refills. How to Request an Expedited Formulary Exception Review You may request an expedited review if a delay could significantly increase the risk to your health or your ability to regain maximum function, or you are undergoing a current course of treatment with a drug not on our formulary. Please indicate “urgent” on the Coverage Exception form or inform Customer Service of the urgent nature of your request. We will respond to you with a determination within twenty-four (24) hours following receipt of the request. For expedited exception reviews, if the exception is approved, we will cover the prescription drug for the duration of the exigency. For both standard and expedited exception reviews, if we grant your request for a formulary exception, the amount you pay will be the copayment at the highest formulary tier in your plan. Other applicable benefit requirements, such as step therapy, are not waived by this exception and must be reviewed separately. If we deny your request for a formulary exception, we will notify you with information on how to appeal our decision, including external appeal information.

  • Inspection and Testing Each Constructing Entity shall cause inspection and testing of the Interconnection Facilities that it constructs in accordance with the provisions of this section. The Construction Parties acknowledge and agree that inspection and testing of facilities may be undertaken as facilities are completed and need not await completion of all of the facilities that a Constructing Entity is building.

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK Firms and/or individuals that assisted in the development or drafting of the specifications, requirements, statements of work, or solicitation documents contained herein are excluded from competing for this solicitation. This shall not be applicable to firms and/or individuals providing responses to a publicly posted Request for Information (RFI) associated with a solicitation.

  • FABRICATION Making up data or results and recording or reporting them.

  • Protocols Each party hereby agrees that the inclusion of additional protocols may be required to make this Agreement specific. All such protocols shall be negotiated, determined and agreed upon by both parties hereto.

  • Maintenance and Testing 54.5.1. Sprint is only responsible for maintaining the facilities that it owns.

Time is Money Join Law Insider Premium to draft better contracts faster.